These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33534258)

  • 1. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a).
    Wilson DP; Koschinsky ML; Moriarty PM
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):159-173. PubMed ID: 33534258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R; Heibges A; Fassbender C;
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Tsimikas S; Stroes ESG
    Atherosclerosis; 2020 May; 300():1-9. PubMed ID: 32234580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U; Schlabs T; Rosada A; Steinhagen-Thiessen E
    Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) as a cardiovascular risk factor: current status.
    Nordestgaard BG; Chapman MJ; Ray K; Borén J; Andreotti F; Watts GF; Ginsberg H; Amarenco P; Catapano A; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A;
    Eur Heart J; 2010 Dec; 31(23):2844-53. PubMed ID: 20965889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
    Fras Z
    Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement.
    Ma GS; Wilkinson MJ; Reeves RR; Yeang C; DeMaria AN; Cotter B; Patel M; Mahmud E; Tsimikas S
    Angiology; 2019 Apr; 70(4):332-336. PubMed ID: 30700108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The re-emergence of lipoprotein(a) in a broader clinical arena.
    Tsimikas S
    Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis-Brief Report.
    Afshar M; Kamstrup PR; Williams K; Sniderman AD; Nordestgaard BG; Thanassoulis G
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2421-2423. PubMed ID: 27765771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperlipoproteinemia(a): clinical significance and treatment options.
    Berthold HK; Gouni-Berthold I
    Atheroscler Suppl; 2013 Jan; 14(1):1-5. PubMed ID: 23357133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. To test, or not to test: that is the question for the future of lipoprotein(a).
    Ellis KL; Chakraborty A; Moses EK; Watts GF
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):241-250. PubMed ID: 30916582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
    Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
    Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
    Hung MY; Tsimikas S
    Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein(a) in nephrological patients.
    Hohenstein B
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):27-30. PubMed ID: 28181057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of and treatment options for increased lipoprotein(a)].
    Zsíros N; Paragh G; Harangi M
    Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.
    Schmitz G; Orsó E
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):21-5. PubMed ID: 25708587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
    Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
    Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
    Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
    Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E; Hohenstein B; Julius U
    Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.